Measuring Cortisol in Saliva of People With Hard-to-Control Type 2 Diabetes
Studies cortisol levels in saliva and blood sugar control in adults with type 2 diabetes.
Plain-language title generated from the registry record
Registry title: Salivary Cortisol and Hypercortisolism in Type 2 Diabetes
Key facts
- Where
- Shanghai, ChinaSee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 80 years old?
Source: NCT07156370, who can take part
Where in China
- Shanghai Sixth People's HospitalShanghai, ChinaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Shanghai 6th People's Hospital
- Trial code
- NCT07156370
- Record updated
- 27 July 2026
- Original description
The goal of this observational study is to explore the prevalence of hypercortisolism in a population with difficult to control type 2 diabetes despite receiving standard-of-care therapies. Additionally, the study will evaluate the correlation between salivary cortisol levels and glycemic control.Read full original descriptionShow less
Study to Explore the Prevalence of Hypercortisolism in Patients With Type 2 Diabetes and Assess the Correlation Between Salivary Cortisol and Glucose Levels
The goal of this observational study is to explore the prevalence of hypercortisolism in a population with difficult to control type 2 diabetes despite receiving standard-of-care therapies. Additionally, the study will evaluate the correlation between salivary cortisol levels and glycemic control.
Inclusion: Aged between 18 and 80 years; Meets the definition of difficult to control type 2 diabetes:; HbA1c level between 7.5% and 11.5%, AND Taking 3 or more anti-hyperglycemic drugs. OR Taking insulin and other anti-hyperglycemic drugs. OR Taking 2 or more anti-hyperglycemic drugs AND a.) the presence of 1 or more micro-vascular or macro-vascular complication (retinopathy, diabetic nephropathy and chronic kidney disease, diabetic neuropathy, atherosclerotic heart disease with diabetes); AND/OR b.) concomitant hypertension requiring 2 or more anti-hypertension medications.
Exclusion: A known diagnosis of Cushing's syndrome, or currently receiving treatment with any of the following: mifepristone, metyrapone, osilodrostat, ketoconazole, fluconazole, aminoglutethimide, etomidate, octreotide, larazotide, long-acting octreotide, or pasireotide; Patients with Type 1 diabetes, new-onset diabetes (<1 year duration), or other specific types of diabetes; History of systemic glucocorticoid use within the last 3 months (inhaled or topical agents are not exclusionary); Presence of severe cardiac, hepatic, renal, or other major organ dysfunction; History of acute diabetic complications, such as diabetic ketoacidosis or hyperosmolar hyperglycemic state, within the last 3 months; Presence of diseases that significantly affect metabolism, such as malignancy or autoimmune disorders; Inability to tolerate adhesive tape, severe skin conditions at the sensor placement site, or presence of a psychiatric illness or cognitive impairment that would interfere with study compliance; Known allergy or severe reaction to dexamethasone; Pregnant or lactating; Excessive alcohol consumption (defined as >14 units per week for males or >7 units per week for females); Severe, untreated sleep apnea; Night shift workers (defined as being awake between 11:00 PM and 7:00 AM).